FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119926677> ?p ?o ?g. }

• W3119926677 endingPage "1850" @default.
• W3119926677 startingPage "1841" @default.
• W3119926677 abstract "Osteoporosis is a silent disorder with dire consequences, and glucocorticoid use remains the most common iatrogenic cause illustrated by the fact that 30% to 50% of subjects on such long-term therapy experience fractures (Oimomi M, Nakamichi T, Ohara T, Sakai M, Igaki N, Hata F, et al. Fructose-related glycation. Diabetes Res Clin Pract 1989;7:137-9; Reid IR. Glucocorticoid osteoporosis--mechanisms and management. Eur J Endocrinol 1997;137:209-17). By directly affecting bone quality while actively used, glucocorticoids increase the risk of fracture that is independent of a subject's bone density status at the time (Weinstein RS. True strength. J Bone Miner Res 2000;15:621-5). A large number of subjects seen in an allergy and immunology clinic have asthma, chronic rhinosinusitis, or other chronic inflammatory diseases, necessitating the use of these medications and placing them at higher risk for this disease. Data on the effects of both oral and inhaled glucocorticoids on fracture risk are presented. This review concretizes the importance of osteoporosis, its pathophysiology, and provides practical guidelines to prevent and treat it. Management recommendations are tailored to 2 different age groups. The first group consists of children, adolescents, and adults 40 years or younger with a focus on attaining peak bone mass. The second group consists of adults 40 years or older where the use of imaging modalities and Fracture Risk Assessment Tool scores helps triage subjects into fracture risk categories. Those at moderate to high risk require bone-sparing medications. Universal preventive measures for both groups are reviewed. Complicated and severe cases may need additional expertise by an endocrinologist or rheumatologist. Osteoporosis is a silent disorder with dire consequences, and glucocorticoid use remains the most common iatrogenic cause illustrated by the fact that 30% to 50% of subjects on such long-term therapy experience fractures (Oimomi M, Nakamichi T, Ohara T, Sakai M, Igaki N, Hata F, et al. Fructose-related glycation. Diabetes Res Clin Pract 1989;7:137-9; Reid IR. Glucocorticoid osteoporosis--mechanisms and management. Eur J Endocrinol 1997;137:209-17). By directly affecting bone quality while actively used, glucocorticoids increase the risk of fracture that is independent of a subject's bone density status at the time (Weinstein RS. True strength. J Bone Miner Res 2000;15:621-5). A large number of subjects seen in an allergy and immunology clinic have asthma, chronic rhinosinusitis, or other chronic inflammatory diseases, necessitating the use of these medications and placing them at higher risk for this disease. Data on the effects of both oral and inhaled glucocorticoids on fracture risk are presented. This review concretizes the importance of osteoporosis, its pathophysiology, and provides practical guidelines to prevent and treat it. Management recommendations are tailored to 2 different age groups. The first group consists of children, adolescents, and adults 40 years or younger with a focus on attaining peak bone mass. The second group consists of adults 40 years or older where the use of imaging modalities and Fracture Risk Assessment Tool scores helps triage subjects into fracture risk categories. Those at moderate to high risk require bone-sparing medications. Universal preventive measures for both groups are reviewed. Complicated and severe cases may need additional expertise by an endocrinologist or rheumatologist." @default.
• W3119926677 created "2021-01-18" @default.
• W3119926677 creator A5014470416 @default.
• W3119926677 creator A5038625247 @default.
• W3119926677 creator A5071320731 @default.
• W3119926677 date "2021-05-01" @default.
• W3119926677 modified "2023-09-25" @default.
• W3119926677 title "Practical Guidance for Prevention and Management of Glucocorticoid-Induced Osteoporosis for the Allergist/Immunologist" @default.
• W3119926677 cites W1852304021 @default.
• W3119926677 cites W1957467225 @default.
• W3119926677 cites W1971444824 @default.
• W3119926677 cites W1975142562 @default.
• W3119926677 cites W1980134556 @default.
• W3119926677 cites W1980418071 @default.
• W3119926677 cites W1980904837 @default.
• W3119926677 cites W1984126393 @default.
• W3119926677 cites W1985500418 @default.
• W3119926677 cites W1989553857 @default.
• W3119926677 cites W1992310701 @default.
• W3119926677 cites W1993913510 @default.
• W3119926677 cites W1998023570 @default.
• W3119926677 cites W1998891056 @default.
• W3119926677 cites W2004782061 @default.
• W3119926677 cites W2005123937 @default.
• W3119926677 cites W2005432197 @default.
• W3119926677 cites W2009758340 @default.
• W3119926677 cites W2011629184 @default.
• W3119926677 cites W2020134388 @default.
• W3119926677 cites W2024652279 @default.
• W3119926677 cites W2038420099 @default.
• W3119926677 cites W2042087486 @default.
• W3119926677 cites W2057909047 @default.
• W3119926677 cites W2059897304 @default.
• W3119926677 cites W2065388026 @default.
• W3119926677 cites W2066403429 @default.
• W3119926677 cites W2078026864 @default.
• W3119926677 cites W2078718256 @default.
• W3119926677 cites W2079777402 @default.
• W3119926677 cites W2079819294 @default.
• W3119926677 cites W2082425621 @default.
• W3119926677 cites W2099379311 @default.
• W3119926677 cites W2102667270 @default.
• W3119926677 cites W2103884329 @default.
• W3119926677 cites W2105362750 @default.
• W3119926677 cites W2105648357 @default.
• W3119926677 cites W2108073684 @default.
• W3119926677 cites W2109228949 @default.
• W3119926677 cites W2109284496 @default.
• W3119926677 cites W2110284715 @default.
• W3119926677 cites W2114575674 @default.
• W3119926677 cites W2114897919 @default.
• W3119926677 cites W2116751183 @default.
• W3119926677 cites W2117334048 @default.
• W3119926677 cites W2124011858 @default.
• W3119926677 cites W2124070987 @default.
• W3119926677 cites W2142865003 @default.
• W3119926677 cites W2143096094 @default.
• W3119926677 cites W2146209160 @default.
• W3119926677 cites W2149512462 @default.
• W3119926677 cites W2149726839 @default.
• W3119926677 cites W2169251377 @default.
• W3119926677 cites W2171133944 @default.
• W3119926677 cites W2179896554 @default.
• W3119926677 cites W2314674563 @default.
• W3119926677 cites W2341958510 @default.
• W3119926677 cites W2414426861 @default.
• W3119926677 cites W2531903877 @default.
• W3119926677 cites W2547169855 @default.
• W3119926677 cites W2587374769 @default.
• W3119926677 cites W2588906490 @default.
• W3119926677 cites W2606085194 @default.
• W3119926677 cites W2609137065 @default.
• W3119926677 cites W2620689898 @default.
• W3119926677 cites W2624963411 @default.
• W3119926677 cites W2743295977 @default.
• W3119926677 cites W2769260297 @default.
• W3119926677 cites W2777736656 @default.
• W3119926677 cites W2786658869 @default.
• W3119926677 cites W2810327208 @default.
• W3119926677 cites W2889603795 @default.
• W3119926677 cites W2920578295 @default.
• W3119926677 cites W2936396720 @default.
• W3119926677 cites W2966522446 @default.
• W3119926677 cites W3010475469 @default.
• W3119926677 cites W3029301343 @default.
• W3119926677 cites W3036836496 @default.
• W3119926677 cites W3086111808 @default.
• W3119926677 cites W3144695097 @default.
• W3119926677 cites W4235755338 @default.
• W3119926677 doi "https://doi.org/10.1016/j.jaip.2020.12.050" @default.
• W3119926677 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33444813" @default.
• W3119926677 hasPublicationYear "2021" @default.
• W3119926677 type Work @default.
• W3119926677 sameAs 3119926677 @default.
• W3119926677 citedByCount "7" @default.
• W3119926677 countsByYear W31199266772021 @default.
• W3119926677 countsByYear W31199266772022 @default.
• W3119926677 countsByYear W31199266772023 @default.

• next